Liraglutide in Children and Adolescents with Type 2 Diabetes

This randomized, double blind, placebo controlled trial evaluated the efficacy and safety of liraglutide in children and adolescents (aged 10 17 years) with type 2 diabetes inadequately controlled by metformin (with or without basal insulin). Participants received subcutaneous liraglutide (up to 1.8 mg/day) or placebo for 26 weeks, followed by a 26-week open-label extension. The primary endpoint was the change in glycated hemoglobin (HbA1c) levels at 26 weeks. Results showed a significant reduction in HbA1c with liraglutide (0.64 percentage points) compared to an increase with placebo (+0.42 percentage points), yielding an estimated treatment difference of 1.06 percentage points (P<0.001). Liraglutide also improved fasting plasma glucose levels and increased the proportion of patients achieving HbA1c <7.0%. However, gastrointestinal adverse events were more frequent with liraglutide. The study concluded that liraglutide is effective for glycemic control in youth with type 2 diabetes but is associated with higher rates of gastrointestinal side effects.

This randomized, double blind, placebo controlled trial evaluated the efficacy and safety of liraglutide in children and adolescents (aged 10 17 years) with type 2 diabetes inadequately controlled by metformin (with or without basal insulin). Participants received subcutaneous liraglutide (up to 1.8 mg/day) or placebo for 26 weeks, followed by a 26-week open-label extension. The primary endpoint was the change in glycated hemoglobin (HbA1c) levels at 26 weeks. Results showed a significant reduction in HbA1c with liraglutide (0.64 percentage points) compared to an increase with placebo (+0.42 percentage points), yielding an estimated treatment difference of 1.06 percentage points (P<0.001). Liraglutide also improved fasting plasma glucose levels and increased the proportion of patients achieving HbA1c <7.0%. However, gastrointestinal adverse events were more frequent with liraglutide. The study concluded that liraglutide is effective for glycemic control in youth with type 2 diabetes but is associated with higher rates of gastrointestinal side effects.